In patients with type 2 diabetes (T2D)👉👉 combination therapy with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and thiazolidinediones was associated with a reduced risk for all-cause mortality, cardiovascular mortality, and major adverse cardiovascular events (MACEs) compared with those who used none or one of these therapies.